retatrutide clinical trial us Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide Phase 3: 60% Achieved

What factors should clinicians consider when weighing the benefits of prescribing GLP-1 agonists against the potential risks of pancreatitis in patients with a history of this condition

The report identified some 83 online companies and medical spas, with 95% of them offering GLP-1-like therapies

doi: 10.14814/phy2.14500

Pushing to 12mg makes sense for those who tolerate 8mg well and need maximum efficacy, but starting there courts unnecessary discomfort

Others may require ongoing treatment to prevent weight regain

Selection of patients : It may be that benefits are strongest in those with early metabolic dysfunction, mild cognitive impairment, or early Alzheimers disease, rather than in advanced dementia